Physician profile
Lois Wilderman
NPI 1497837462
$2,261.80
in general payments reported to CMS, 2019-2025
16 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $465 · 2022: $430 · 2023: $529 · 2024: $355 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $357.16 | 2023-2025 | Korlym |
| Novo Nordisk INC | $316.12 | 2022-2025 | Wegovy |
| Lilly USA, LLC | $207.33 | 2023-2024 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.24 | 2021-2022 | |
| Esperion Therapeutics, INC. | $124.99 | 2021 | |
| Abbott Laboratories | $124.98 | 2024 | Freestyle Libre 3 |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.98 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $122.74 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $120.52 | 2023 | Austedo Xr |
| Astrazeneca Pharmaceuticals Lp | $117.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.79 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $113.06 | 2021 | |
| Paratek Pharmaceuticals, INC. | $83.33 | 2022 | |
| Dexcom, INC. | $79.31 | 2022 | |
| Medtronic, INC. | $78.63 | 2023 | Harmony |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $36.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lois Wilderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.